A Study to Evaluate the Efficacy and Safety of CJC-1134-PC in Patients With Type 2 Diabetes Who Are Currently on Metformin Monotherapy
NCT00674466
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
90
Enrollment
INDUSTRY
Sponsor class
Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG:
1.5 mg or 2.0 mg CJC-1134-PC
DRUG:
Placebo
Sponsor
ConjuChem